I mean we’re still very, very early in the rollout and the penetration rates in that market, even more modest at this stage than what we see here in the U.S. It is clearly included in the guidance, as you first talked about. I don’t think, we’ll break out specifically necessarily the dollar amount, but we would continue to anticipate robust growth internationally driven by primarily at this point, still Western Europe. Pricing has been candidly better than we had anticipated when we got started internationally a couple of years ago. In Europe, we have a mix of primarily direct markets, and then we’re indirect in some of the southern European markets, for instance. But by and large, the margin profile has come together much more strongly than even we had anticipated, doesn’t quite compare to the U.S. margin.
So it does factor into the longer-term degradation in the margin that you’ve heard us talk about. But I think we’ve been pleased with the pricing landscape in Europe. And then on top of Europe, as you look more broadly internationally, we continue to do work from a regulatory standpoint to get on market in Japan and China. We’re increasingly focused on exploring what the go-to-market strategy will be in those two respective markets. And then we’re opportunistically continuing to do cases and add new markets. Globally, I think we’re north of 20-some markets now in total internationally. So, we’re doing cases now in Australia and New Zealand, Singapore, Chile, Colombia, a fairly large list now, all still relatively early. But again, this is a key growth driver for us.
And I think over time, we’ll be an increasingly important contributor not only to our growth, but also the kind of clinical impact we’re having on patients.
Marie Thibault: Okay, that’s really helpful. Thank you.
Mitch Hill: Sorry, Marie, just to add, I made a brief comment there about the portion of our operating loss. It’s kind of related to the international business. We believe that this is a very worthwhile and significant and important investment for the company. And that’s why we’re willing to kind of deal with that. And as time goes on, we believe this will actually be a significant part of the company’s overall revenue picture. And so, I think that could be a few years, hence, obviously. But we’re very excited about the international prospects for the business, and we see some really positive developments for the business coming up in 2023.
Marie Thibault: Okay, very helpful, thank you for that. Maybe my follow-up here, if you could give us any details, it’s hard for us to track given we don’t have a lot of real numbers from some of your competitors. What is your latest market research on sort of market penetration of VTE and then your own market share within that penetrated portion at this point, any detail there is helpful? Thank you.
Drew Hykes: Yes, Marie. I’ll do our best. As you point out, it’s sometimes a difficult market to triangulate on the – most of the competitors have their results kind of buried within much larger portfolio. So we believe if you start at the highest level of the overall incidence of VTE, we believe that market is growing in the low single-digits alongside population growth. If you look at the penetration within that broad group of patients of any interventional therapy today, both legacy lytic-based interventions as well as mechanical thrombectomy interventions like Inari, we believe in both DVT and PE, the interventional penetration is still somewhere between 10% and 15%, very, very modest, vast majority of patients still getting treated with conservative medical management and coagulation alone.
If you look at just then this sliver of interventional treatment, we believe lytics still today are being used in nearly half of those interventions, still today despite all the traction of mechanical thrombectomy. And if you looked at mechanical thrombectomy as a subset of that interventional market, we believe that segment is growing easily at 20%. So, those numbers are all estimates and come with a fair amount of art and science to arrive at those estimates, but hopefully, that gives you some sense of how, we view the market and some of the estimates that we’re making across the board.
Marie Thibault: All right, thank you.
